Hao Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hao Yuan has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Chuanzhi Duan
Zhujiang Hospital, Southern Medical University
6 shared publications - Mengshi Huang
Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China
5 shared publications - Runze Ge
Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China
5 shared publications - Xifeng Li
Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China
5 shared publications - Xin Feng
Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China
5 shared publications - Aihua Liu
Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University
4 shared publications
Latest Publications
- 19 September 2026
- Published by Springer Nature in Neuroradiology
- p. 1-10
Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study
Background Pipeline Flex Embolization Device with Shield Technology (PED Shield) is designed to reduce the incidence of thrombosis events through phosphorylcholine coating. However, the comparative efficacy and safety of PED Shield and PED/PED Flex remain unclear. Methods We conducted a retrospective analysis of a prospectively maintained database at three advanced stroke centers from February 2016 to October 2024. Propensity score matching was employed to adjust for sex, age, hypertension, diabetes, hyperlipidemia, smoking, aneurysm location, morphology, size, coiling and follow-up duration. After matching, perioperative complications and clinical and angiographic outcomes were compared. Results 1039 patients treated by PED/PED Flex and 172 patients treated by PED Shield were enrolled. For clinical outcomes, 164 pairs were matched. No significant differences were found in total perioperative complications (7.9% vs. 4.9%, p = 0.259) and favourable prognosis (mRS score 0–2, 98.0% vs. 97.5%, p = 0.760) between the PED Shield and PED/PED Flex group. For angiographic outcomes, 121 pairs were matched. No significant differences were observed in complete occlusion (80.2% vs. 73.6%, p = 0.223), significant in-stent stenosis (ISS, ISS rate > 50%) (3.3% vs. 5.0%, p = 0.749) and symptomatic ISS (0.0% vs. 2.5%, p = 0.247) between the PED Shield and PED/PED Flex group. However, PED Shield had a lower incidence of ISS (ISS rate ≥ 25%, 5.0 vs. 14.9%, p = 0.010) at a mean follow-up time of 6–7 months. Conclusion Compared with PED/PED Flex, PED Shield has a lower rate of ISS at a mean follow-up time of 6–7 months. No significant differences are observed in perioperative complications, clinical outcomes, complete occlusion, significant ISS and symptomatic ISS. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT06446778.
- 19 September 2026
- Published by Springer Nature in Neuroradiology
- p. 1-10
Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study
Background Pipeline Flex Embolization Device with Shield Technology (PED Shield) is designed to reduce the incidence of thrombosis events through phosphorylcholine coating. However, the comparative efficacy and safety of PED Shield and PED/PED Flex remain unclear. Methods We conducted a retrospective analysis of a prospectively maintained database at three advanced stroke centers from February 2016 to October 2024. Propensity score matching was employed to adjust for sex, age, hypertension, diabetes, hyperlipidemia, smoking, aneurysm location, morphology, size, coiling and follow-up duration. After matching, perioperative complications and clinical and angiographic outcomes were compared. Results 1039 patients treated by PED/PED Flex and 172 patients treated by PED Shield were enrolled. For clinical outcomes, 164 pairs were matched. No significant differences were found in total perioperative complications (7.9% vs. 4.9%, p = 0.259) and favourable prognosis (mRS score 0–2, 98.0% vs. 97.5%, p = 0.760) between the PED Shield and PED/PED Flex group. For angiographic outcomes, 121 pairs were matched. No significant differences were observed in complete occlusion (80.2% vs. 73.6%, p = 0.223), significant in-stent stenosis (ISS, ISS rate > 50%) (3.3% vs. 5.0%, p = 0.749) and symptomatic ISS (0.0% vs. 2.5%, p = 0.247) between the PED Shield and PED/PED Flex group. However, PED Shield had a lower incidence of ISS (ISS rate ≥ 25%, 5.0 vs. 14.9%, p = 0.010) at a mean follow-up time of 6–7 months. Conclusion Compared with PED/PED Flex, PED Shield has a lower rate of ISS at a mean follow-up time of 6–7 months. No significant differences are observed in perioperative complications, clinical outcomes, complete occlusion, significant ISS and symptomatic ISS. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT06446778.
- Open Access
- 18 September 2026
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 24 (September) , 1-15
Circulating proteins as key genetically proxied mediators in the pathway from smoking to intracranial aneurysm disease: A mediation Mendelian randomization analysis
Introduction: The molecular mechanisms linking smoking to intracranial aneurysmal disease remain elusive. In this study, we aimed to employ Mendelian randomization (MR) analysis to identify proteomic pathways that mediate this relationship. Methods: We conducted a two-step, two-sample MR...
- 18 September 2026
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 24 (September) , 1-15
Open AccessCirculating proteins as key genetically proxied mediators in the pathway from smoking to intracranial aneurysm disease: A mediation Mendelian randomization analysis
Introduction: The molecular mechanisms linking smoking to intracranial aneurysmal disease remain elusive. In this study, we aimed to employ Mendelian randomization (MR) analysis to identify proteomic pathways that mediate this relationship. Methods: We conducted a two-step, two-sample MR...
- Open Access
H-Type Hypertension and Aneurysm Instability: An Observational and Genetic Study
Background: Unruptured intracranial aneurysms (UIAs) pose a significant risk of subarachnoid hemorrhage. Both hypertension and hyperhomocysteinemia are recognized as independent risk factors for vascular disease; however, their combined impact (H-type hypertension) on aneurysm instability and rupture remains unclear. Methods: We analyzed a prospective cohort of 358 adults with UIAs (475 aneurysms) using high-resolution vessel-wall MRI (HRVWI) for cross-sectional and longitudinal assessment. H-type hypertension was defined as hypertension with plasma homocysteine ≥10 μmol/L. Multivariable logistic regression assessed associations with AWE and aneurysm growth (longitudinal sub-cohort: n = 82, 89 aneurysms). Mendelian randomization (MR) analyses evaluated the causal role of homocysteine in hypertension and aSAH. Proteomic profiling identified potential molecular mechanisms. Results: AWE occurred in 33.7% of aneurysms, which were larger, irregular, and had higher PHASES scores. Elevated homocysteine (10.3 vs 9.5 μmol/L, p = 0.004) and H-type hypertension (43.8% vs 28.3%, p < 0.001) were associated with AWE. After adjustment, H-type hypertension independently predicted AWE (OR = 3.18) and aneurysm growth (OR = 3.63). MR analyses showed homocysteine increased aSAH (OR = 1.39) and hypertension risk (OR = 1.10), while hypertension increased aSAH risk (OR = 1.58). Mediation analysis did not support hypertension as a mediator (p = 0.20). Proteomic analyses identified key pathways related to inflammation–immune dysregulation, extracellular matrix remodeling, and signaling activation as potential mediators. Conclusions: H-type hypertension amplifies aneurysmal-wall instability and growth. Combined control of blood pressure and homocysteine merits prospective evaluation for UIA prevention.
Open AccessH-Type Hypertension and Aneurysm Instability: An Observational and Genetic Study
Background: Unruptured intracranial aneurysms (UIAs) pose a significant risk of subarachnoid hemorrhage. Both hypertension and hyperhomocysteinemia are recognized as independent risk factors for vascular disease; however, their combined impact (H-type hypertension) on aneurysm instability and rupture remains unclear. Methods: We analyzed a prospective cohort of 358 adults with UIAs (475 aneurysms) using high-resolution vessel-wall MRI (HRVWI) for cross-sectional and longitudinal assessment. H-type hypertension was defined as hypertension with plasma homocysteine ≥10 μmol/L. Multivariable logistic regression assessed associations with AWE and aneurysm growth (longitudinal sub-cohort: n = 82, 89 aneurysms). Mendelian randomization (MR) analyses evaluated the causal role of homocysteine in hypertension and aSAH. Proteomic profiling identified potential molecular mechanisms. Results: AWE occurred in 33.7% of aneurysms, which were larger, irregular, and had higher PHASES scores. Elevated homocysteine (10.3 vs 9.5 μmol/L, p = 0.004) and H-type hypertension (43.8% vs 28.3%, p < 0.001) were associated with AWE. After adjustment, H-type hypertension independently predicted AWE (OR = 3.18) and aneurysm growth (OR = 3.63). MR analyses showed homocysteine increased aSAH (OR = 1.39) and hypertension risk (OR = 1.10), while hypertension increased aSAH risk (OR = 1.58). Mediation analysis did not support hypertension as a mediator (p = 0.20). Proteomic analyses identified key pathways related to inflammation–immune dysregulation, extracellular matrix remodeling, and signaling activation as potential mediators. Conclusions: H-type hypertension amplifies aneurysmal-wall instability and growth. Combined control of blood pressure and homocysteine merits prospective evaluation for UIA prevention.
- 22 December 2025
- Published by Springer Nature in Neuroradiology
- Vol. 68 (1) , 253-262
Sex difference in predictors of aneurysmal wall enhancement: a cross-sectional and prospective cohort study
Background Aneurysm wall enhancement (AWE) is a potential imaging biomarker that can be used to identify intracranial aneurysms with an increased risk of rupture. Factors and mechanisms causing intracranial aneurysms to rupture or progress differ between women and men. Thus, we performed a cross-sectional and prospective cohort study to identify the risk factors predicting AWE in men and women. Methods Consecutive patients with unruptured intracranial aneurysms were prospectively recruited from September 2022 to September 2024. Baseline characteristics were collected through a standard questionnaire. Multivariate logistic regression was performed to assess the predictors of aneurysmal wall enhancement in men and women. Results A total of 332 patients with 435 intracranial aneurysms were included. In the multiple logistic regression analysis, obesity (OR = 2.88, 95% CI 1.06–7.81, P = 0.038), the history of hypertension (OR = 2.76, 95% CI 1.16–6.57, P = 0.022) and younger age (OR = 0.96, 95% CI 0.93-1.00, p = 0.035) were independent risk factors for AWE in men. Meanwhile, drinking habit (OR = 2.64, 95% CI 1.09–6.41, P = 0.032), the family history of intracranial aneurysm (OR = 4.01, 95% CI 1.21–13.36, P = 0.024) and older age (OR = 1.04, 95% CI 1.01–1.07, P = 0.009) were independent risk factors for AWE in women. Conclusion This study clearly demonstrates a significant sexual dimorphism in the risk factors associated with AWE. These findings underscore the necessity for sex-specific risk stratification models for intracranial aneurysm management, suggesting that men and women have specific lifestyle interventions to prevent the progression or rupture of intracranial aneurysms.
- 22 December 2025
- Published by Springer Nature in Neuroradiology
- Vol. 68 (1) , 253-262
Sex difference in predictors of aneurysmal wall enhancement: a cross-sectional and prospective cohort study
Background Aneurysm wall enhancement (AWE) is a potential imaging biomarker that can be used to identify intracranial aneurysms with an increased risk of rupture. Factors and mechanisms causing intracranial aneurysms to rupture or progress differ between women and men. Thus, we performed a cross-sectional and prospective cohort study to identify the risk factors predicting AWE in men and women. Methods Consecutive patients with unruptured intracranial aneurysms were prospectively recruited from September 2022 to September 2024. Baseline characteristics were collected through a standard questionnaire. Multivariate logistic regression was performed to assess the predictors of aneurysmal wall enhancement in men and women. Results A total of 332 patients with 435 intracranial aneurysms were included. In the multiple logistic regression analysis, obesity (OR = 2.88, 95% CI 1.06–7.81, P = 0.038), the history of hypertension (OR = 2.76, 95% CI 1.16–6.57, P = 0.022) and younger age (OR = 0.96, 95% CI 0.93-1.00, p = 0.035) were independent risk factors for AWE in men. Meanwhile, drinking habit (OR = 2.64, 95% CI 1.09–6.41, P = 0.032), the family history of intracranial aneurysm (OR = 4.01, 95% CI 1.21–13.36, P = 0.024) and older age (OR = 1.04, 95% CI 1.01–1.07, P = 0.009) were independent risk factors for AWE in women. Conclusion This study clearly demonstrates a significant sexual dimorphism in the risk factors associated with AWE. These findings underscore the necessity for sex-specific risk stratification models for intracranial aneurysm management, suggesting that men and women have specific lifestyle interventions to prevent the progression or rupture of intracranial aneurysms.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 3002-3013
Effect of LDL-Cholesterol Levels and Oral Atorvastatin on Outcomes After Pipeline Therapy for Intracranial Aneurysms
BACKGROUND: We aimed to determine the effects of statin treatment on outcomes of pipeline embolization device therapy for intracranial aneurysms in relation to LDL (low-density lipoprotein) cholesterol levels. METHODS: Using data from the SESIA registry (Safety and Efficacy of Stent Deployment for Intracranial Aneurysms), we enrolled participants who underwent pipeline embolization device implantation at 4 centers in China (2018–2022). Statin users (atorvastatin 20 mg daily, for ≥3 days and ≥6 months preprocedurally and postprocedurally, respectively) were matched with nonstatin users (1:1) using propensity scores and further adjusted by inverse probability of treatment weighting, balancing for baseline characteristics, procedural details, and lipid levels (based on East Asian profiles). Study outcomes include perioperative complications, aneurysmal occlusion, in-stent stenosis, and clinical prognosis at the latest follow-up. Multivariable analyses using logistic and Cox regression models adjusted for these factors in both prematched and postmatched cohorts, evaluating the role of lipid modification in subgroups. RESULTS: Of the 1558 patients screened, 1193 (53.75±11.07 years, 69.4% females; statin: n=603, nonstatin: n=590) were enrolled with 3- to 48-month follow-up. In the matched cohort (352 pairs), statin treatment reduced the incidences of perioperative cerebrovascular (2.0% versus 8.5%, P =0.001) and follow-up ischemic (1.7% versus 5.1%, P =0.020) complications. Multivariable analyses in participants with baseline LDL-cholesterol ≥2.59 mmol/L showed that statin treatment was associated with fewer perioperative cerebrovascular complications (odds ratio, 0.371 [95% CI, 0.195–0.705]; P =0.002), in-stent stenosis (hazard ratio, 0.433 [95% CI, 0.269–0.698]; P =0.001), and follow-up ischemic events (hazard ratio, 0.315 [95% CI, 0.135–0.733]; P =0.007; P values for interaction were 0.671, 0.009, and 0.507, respectively, versus <2.59 mmol/L). Postmatched analyses confirmed consistency for perioperative cerebrovascular complications (odds ratio, 0.416 [95% CI, 0.211–0.821]), in-stent stenosis (hazard ratio, 0.397 [95% CI, 0.232–0.667]), and follow-up ischemic events (hazard ratio, 0.364 [95% CI, 0.148–0.895]). CONCLUSIONS: Atorvastatin treatment improved postpipeline embolization device-deployment outcomes by reducing ischemic events, particularly in patients with elevated LDL-cholesterol. The long-term benefits of adjunctive statin use in this population warrant further investigation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387995.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 3002-3013
Open AccessEffect of LDL-Cholesterol Levels and Oral Atorvastatin on Outcomes After Pipeline Therapy for Intracranial Aneurysms
BACKGROUND: We aimed to determine the effects of statin treatment on outcomes of pipeline embolization device therapy for intracranial aneurysms in relation to LDL (low-density lipoprotein) cholesterol levels. METHODS: Using data from the SESIA registry (Safety and Efficacy of Stent Deployment for Intracranial Aneurysms), we enrolled participants who underwent pipeline embolization device implantation at 4 centers in China (2018–2022). Statin users (atorvastatin 20 mg daily, for ≥3 days and ≥6 months preprocedurally and postprocedurally, respectively) were matched with nonstatin users (1:1) using propensity scores and further adjusted by inverse probability of treatment weighting, balancing for baseline characteristics, procedural details, and lipid levels (based on East Asian profiles). Study outcomes include perioperative complications, aneurysmal occlusion, in-stent stenosis, and clinical prognosis at the latest follow-up. Multivariable analyses using logistic and Cox regression models adjusted for these factors in both prematched and postmatched cohorts, evaluating the role of lipid modification in subgroups. RESULTS: Of the 1558 patients screened, 1193 (53.75±11.07 years, 69.4% females; statin: n=603, nonstatin: n=590) were enrolled with 3- to 48-month follow-up. In the matched cohort (352 pairs), statin treatment reduced the incidences of perioperative cerebrovascular (2.0% versus 8.5%, P =0.001) and follow-up ischemic (1.7% versus 5.1%, P =0.020) complications. Multivariable analyses in participants with baseline LDL-cholesterol ≥2.59 mmol/L showed that statin treatment was associated with fewer perioperative cerebrovascular complications (odds ratio, 0.371 [95% CI, 0.195–0.705]; P =0.002), in-stent stenosis (hazard ratio, 0.433 [95% CI, 0.269–0.698]; P =0.001), and follow-up ischemic events (hazard ratio, 0.315 [95% CI, 0.135–0.733]; P =0.007; P values for interaction were 0.671, 0.009, and 0.507, respectively, versus <2.59 mmol/L). Postmatched analyses confirmed consistency for perioperative cerebrovascular complications (odds ratio, 0.416 [95% CI, 0.211–0.821]), in-stent stenosis (hazard ratio, 0.397 [95% CI, 0.232–0.667]), and follow-up ischemic events (hazard ratio, 0.364 [95% CI, 0.148–0.895]). CONCLUSIONS: Atorvastatin treatment improved postpipeline embolization device-deployment outcomes by reducing ischemic events, particularly in patients with elevated LDL-cholesterol. The long-term benefits of adjunctive statin use in this population warrant further investigation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387995.
- 14 February 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-14
Comparison of Tubridge and Pipeline Embolisation Devices in intracranial aneurysms: a multicentre, propensity-matching analysis on the patency of branch vessels
To compare the impact of two flow diverter devices (Pipeline Embolization Device [PED] and Tubridge Embolization Device [TED]) on branch vessels patency in intracranial aneurysm treatment, with specific focus on branch vessel outcomes and clinical safety. A retrospective analysis of 320 patients with 430 aneurysms and 602 covered branches treated with PED or TED was conducted. Statistical analyses included descriptive statistics and group comparisons. Potential predictors of aneurysm and branch occlusion were identified through univariate analysis followed by multivariate logistic regression. Propensity score matching was adjusted for baseline discrepancies, and the comparative analysis examined stent efficacy on branch vessels patency and clinical outcomes. Stenosis or occlusion rates were 6.1% for the ophthalmic artery (OA), 31.6% for the posterior communicating artery (PComA), 0.9% for the anterior choroidal artery (AChA), 40.5% for the anterior cerebral artery (ACA), and 0% for the middle cerebral (MCA), lenticulostriate (LSA), posterior inferior cerebellar (PICA), and anterior inferior cerebellar arteries (AICA). Before propensity score matching, branch vessels patency rates did not significantly differ between the PED and TED groups. After matching, 109 pairs were identified. No significant differences in angiographic outcomes for distal and proximal branch vessels regarding occlusion or stenosis were observed between groups (P values > 0.999 and 0.332, respectively). Branch obliteration was mostly asymptomatic. PED and TED showed comparable safety profiles and branch vessel patency rates. These findings indicate that FD treatment may be clinically safe for selected ICA and VA cases requiring branch vessel coverage.
- 14 February 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-14
Comparison of Tubridge and Pipeline Embolisation Devices in intracranial aneurysms: a multicentre, propensity-matching analysis on the patency of branch vessels
To compare the impact of two flow diverter devices (Pipeline Embolization Device [PED] and Tubridge Embolization Device [TED]) on branch vessels patency in intracranial aneurysm treatment, with specific focus on branch vessel outcomes and clinical safety. A retrospective analysis of 320 patients with 430 aneurysms and 602 covered branches treated with PED or TED was conducted. Statistical analyses included descriptive statistics and group comparisons. Potential predictors of aneurysm and branch occlusion were identified through univariate analysis followed by multivariate logistic regression. Propensity score matching was adjusted for baseline discrepancies, and the comparative analysis examined stent efficacy on branch vessels patency and clinical outcomes. Stenosis or occlusion rates were 6.1% for the ophthalmic artery (OA), 31.6% for the posterior communicating artery (PComA), 0.9% for the anterior choroidal artery (AChA), 40.5% for the anterior cerebral artery (ACA), and 0% for the middle cerebral (MCA), lenticulostriate (LSA), posterior inferior cerebellar (PICA), and anterior inferior cerebellar arteries (AICA). Before propensity score matching, branch vessels patency rates did not significantly differ between the PED and TED groups. After matching, 109 pairs were identified. No significant differences in angiographic outcomes for distal and proximal branch vessels regarding occlusion or stenosis were observed between groups (P values > 0.999 and 0.332, respectively). Branch obliteration was mostly asymptomatic. PED and TED showed comparable safety profiles and branch vessel patency rates. These findings indicate that FD treatment may be clinically safe for selected ICA and VA cases requiring branch vessel coverage.